Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade F 3.76 -4.81% -0.19
AGEN closed down 4.81 percent on Thursday, April 19, 2018, on 1.64 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 3

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AGEN trend table...

Date Alert Name Type % Chg
Apr 19 Wide Bands Range Expansion 0.00%
Apr 19 Below Lower BB Weakness 0.00%
Apr 19 Down 3 Days in a Row Weakness 0.00%
Apr 19 Down 4 Days in a Row Weakness 0.00%
Apr 19 Lower Bollinger Band Touch Weakness 0.00%
Apr 19 Oversold Stochastic Weakness 0.00%
Apr 18 Stochastic Reached Oversold Weakness -4.81%
Apr 18 Down 3 Days in a Row Weakness -4.81%
Apr 18 Oversold Stochastic Weakness -4.81%
Apr 17 200 DMA Resistance Bearish -8.07%

Older signals for AGEN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.19
52 Week Low 3.24
Average Volume 1,748,584
200-Day Moving Average 4.192
50-Day Moving Average 4.8552
20-Day Moving Average 4.5315
10-Day Moving Average 4.296
Average True Range 0.2858
ADX 35.37
+DI 10.0
-DI 36.5
Chandelier Exit (Long, 3 ATRs ) 5.0326
Chandelier Exit (Short, 3 ATRs ) 4.4874
Upper Bollinger Band 5.2298
Lower Bollinger Band 3.8332
Percent B (%b) -0.05
BandWidth 30.819817
MACD Line -0.2749
MACD Signal Line -0.1898
MACD Histogram -0.0851
Fundamentals Value
Market Cap 374.91 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -2.98
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.33
Resistance 3 (R3) 4.35 4.18 4.24
Resistance 2 (R2) 4.18 4.03 4.17 4.20
Resistance 1 (R1) 3.97 3.95 3.89 3.95 4.17
Pivot Point 3.80 3.80 3.76 3.79 3.80
Support 1 (S1) 3.59 3.65 3.51 3.57 3.35
Support 2 (S2) 3.42 3.57 3.41 3.32
Support 3 (S3) 3.21 3.42 3.29
Support 4 (S4) 3.19